TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.verified

TCRR

Price:

$1.48

Market Cap:

$58.11M

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of ren...[Read more]

Industry

Biotechnology

IPO Date

2019-02-14

Stock Exchange

NASDAQ

Ticker

TCRR

The PE Ratio as of June 2024 (TTM) for TCR2 Therapeutics Inc. (TCRR) is -0.35

According to TCR2 Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.35. This represents a change of -28.71% compared to the average of -0.49 of the last 4 quarters.

TCR2 Therapeutics Inc. (TCRR) Historical PE Ratio (quarterly & annually)

How has TCRR PE Ratio performed in the past?

The mean historical PE Ratio of TCR2 Therapeutics Inc. over the last ten years is -7.05. The current -0.35 PE Ratio has changed 399.49% with respect to the historical average. Over the past ten years (40 quarters), TCRR's PE Ratio was at its highest in in the December 2022 quarter at -0.16. The PE Ratio was at its lowest in in the March 2018 quarter at -14.19.

Quarterly (TTM)
Annual

Average

-7.05

Median

-6.33

Minimum

-14.41

Maximum

-0.25

TCR2 Therapeutics Inc. (TCRR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of TCR2 Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 143.51%

Maximum Annual PE Ratio = -0.25

Minimum Annual Increase = -86.27%

Minimum Annual PE Ratio = -14.41

Quarterly (TTM)
Annual
YearPE RatioChange
2022-0.25-85.65%
2021-1.77-86.27%
2020-12.90103.71%
2019-6.33-56.06%
2018-14.41143.51%
2017-5.92-24.14%

TCR2 Therapeutics Inc. (TCRR) Average PE Ratio

How has TCRR PE Ratio performed in the past?

The current PE Ratio of TCR2 Therapeutics Inc. (TCRR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-4.97

5-year avg

-7.13

10-year avg

-7.05

TCR2 Therapeutics Inc. (TCRR) PE Ratio vs. Peers

How is TCRR’s PE Ratio compared to its peers?

TCR2 Therapeutics Inc.’s PE Ratio is greater than Affimed N.V. (-0.92), greater than Pieris Pharmaceuticals, Inc. (-0.70), greater than ADC Therapeutics SA (-0.99), greater than Agenus Inc. (-1.09), greater than Revolution Medicines, Inc. (-12.83), greater than Black Diamond Therapeutics, Inc. (-3.45), less than Atreca, Inc. (-0.04), greater than Passage Bio, Inc. (-0.64), greater than Harpoon Therapeutics, Inc. (-2.94), greater than Alector, Inc. (-3.31), less than Homology Medicines, Inc. (-0.01), greater than Stoke Therapeutics, Inc. (-6.42),

Build a custom stock screener for TCR2 Therapeutics Inc. (TCRR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TCR2 Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

TCR2 Therapeutics Inc. (TCRR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like TCR2 Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is TCR2 Therapeutics Inc.'s PE Ratio?

How is the PE Ratio calculated for TCR2 Therapeutics Inc. (TCRR)?

What is the highest PE Ratio for TCR2 Therapeutics Inc. (TCRR)?

What is the 3-year average PE Ratio for TCR2 Therapeutics Inc. (TCRR)?

What is the 5-year average PE Ratio for TCR2 Therapeutics Inc. (TCRR)?

How does the current PE Ratio for TCR2 Therapeutics Inc. (TCRR) compare to its historical average?